PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths
- Category: Antibodies
- Published on Monday, 12 August 2019 18:38
- Hits: 569
TARRYTOWN, NY, USA I August 12, 2019 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company was informed by study investigators that a randomized, controlled trial evaluating four investigational therapies for Ebola virus infection was stopped early because REGN-EB3 was superior to ZMapp in preventing death. ZMapp served as the control arm of the trial because it was considered the standard-of-care based on the previous PREVAIL II clinical trial. The protocol specified that the PALM trial would only be stopped early for a highly statistically significant result. The independent data safety monitoring board decided to stop the trial after reviewing interim mortality data from 499 patients. The trial was conducted in the Democratic Republic of Congo (DRC), where the current outbreak is ongoing.
The trial was first initiated in 2018 with three treatment arms: mAb114, remdesivir and ZMapp. The trial protocol was amended after the World Health Organization (WHO) held an Ad-Hoc Expert Consultation to assess all preclinical and clinical data on available investigational products, and recommended the addition of REGN-EB3 as a fourth treatment arm.
"The Regeneron team worked tirelessly to discover, develop and produce REGN-EB3 in record time utilizing our VelocImmune®-based technologies," said Neil Stahl, Ph.D., Executive Vice President of Research and Development at Regeneron. "We are moved to know our therapy is helping save the lives of people facing this deadly infectious disease. We look forward to reviewing the trial data and are working with governments and other collaborators, including BARDA, to make REGN-EB3 available for the current outbreak and future use."
"This trial was conducted in difficult circumstances during a public health emergency, and we appreciate the efforts of the WHO and other experts to add REGN-EB3 to the trial," said Sumathi Sivapalasingam, M.D., Senior Director, Early Clinical Development and Experimental Sciences at Regeneron. "This trial is a remarkable advance in the decades-long struggle to respond to Ebola and we appreciate the tremendous efforts of the many governmental and non-governmental organizations who made it possible."
REGN-EB3 (also known as REGN3470-3471-3479) was invented by Regeneron using its VelociSuite® technologies; the therapy combines three fully-human monoclonal antibodies. REGN-EB3 has received orphan drug designation from both the U.S. Food and Drug Administration and the European Medicines Agency. REGN-EB3 is being developed, tested and manufactured as part of an agreement established in 2015 with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS). REGN-EB3 is currently under clinical development and its safety and efficacy have not been fully evaluated by any regulatory authority.
"REGN-EB3 is a three-antibody cocktail designed with the goal of enhancing efficacy, reducing the development of viral sequences that lead to resistance, and increasing potential utility in future outbreaks as viruses continually evolve," said Christos Kyratsous, Ph.D., Vice President of Research, Infectious Diseases and Viral Vector Technologies at Regeneron. "The Regeneron rapid response infectious disease platform has the opportunity to accelerate our response to future epidemics and pandemics, and we continue to work on additional diseases that may pose a threat to public health."
About the PALM Trial
The PAmoja TuLinde Maisha (PALM [together save lives]) clinical trial was a randomized, multicenter, controlled trial to evaluate the safety and efficacy of four investigational agents for the treatment of patients with Ebola virus infection – including three antibody-based therapies, REGN-EB3, ZMapp and mAb114 (a single monoclonal antibody); and one small molecule antiviral, remdesivir. The primary objective of the trial was to compare mortality in patients with Ebola who received either REGN-EB3, mAb114 or remdesivir to those who received ZMapp in the control arm. The National Institutes of Health (NIH) and the Institut National de Recherche Biomédicale (INRB) in the DRC jointly sponsored and served as co-principal investigators.
By August 2019, the trial had enrolled nearly 700 participants across four Ebola Treatment Centers in the DRC. With the preliminary findings in 499 trial participants, REGN-EB3 and mAb114 will be the two investigational treatments given as part of an Extension Phase to further evaluate safety until final results of the clinical trial are known, after which an Expanded Access Phase will be initiated using the lead therapeutics from the trial.
Regeneron and BARDA have several ongoing research collaborations in addition to the Ebola program, including a collaboration to develop treatments for Middle East Respiratory Syndrome (MERS) and a collaboration for the discovery, research, development and manufacturing of a portfolio of antibodies targeting up to 10 pathogens that pose significant risk to public health.
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
SOURCE: Regeneron Pharmaceuticals